4A1 Stock Overview Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cereno Scientific AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Cereno Scientific Historical stock prices Current Share Price SEK 0.45 52 Week High SEK 0.79 52 Week Low SEK 0.29 Beta 0.36 1 Month Change 2.46% 3 Month Change -1.49% 1 Year Change 2.90% 3 Year Change 5.56% 5 Year Change n/a Change since IPO 58.52%
Recent News & Updates
Cereno Scientific Enters 9 Additional Patients in its Expanded Access Program with CS1 Providing More Long-Term Safety and Efficacy Data in Rare Disease PAH Dec 27
Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014 Nov 14 Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025
Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014 Oct 17
Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling Sep 25
Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025 Sep 19 See more updates
Cereno Scientific Enters 9 Additional Patients in its Expanded Access Program with CS1 Providing More Long-Term Safety and Efficacy Data in Rare Disease PAH Dec 27
Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014 Nov 14 Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025
Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014 Oct 17
Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling Sep 25
Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025 Sep 19
No independent directors Sep 10
Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024 Sep 04
Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension Sep 03 Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025
Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil Aug 16 First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014
Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014 Jun 18
Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025 May 24
Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025 May 03
Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024 Apr 17
Cereno Scientific AB (Publ) Approves Election of New Directors Apr 16
Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014 Apr 10
Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022) Mar 31
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH Mar 22
Cereno Scientific Appoints Don De Bethizy as Board of Directors Mar 15
Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH Mar 06
Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH Feb 29
Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022) Feb 22
Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH Feb 22
New minor risk - Market cap size Feb 14
Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D Feb 13
Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities Feb 03
Cereno Scientific AB Appoints Julia Fransson as Director of Business Development Feb 02
Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension Jan 31
Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director Jan 12
Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH Dec 21 Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024
Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting Dec 13
Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585 Dec 12
Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study Dec 02
Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family Nov 29
Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH Nov 19
Third quarter 2023 earnings released Nov 19
Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH Nov 17
Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member Nov 08
Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH) Oct 14
Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024 Sep 13
New major risk - Shareholder dilution Sep 03
Second quarter 2023 earnings released Aug 27
Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah Aug 24
Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer Aug 22
Cereno Scientific Reports Positive Data from Patient Case Study Jun 30
Chairperson recently bought €68k worth of stock Jun 29
Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH Jun 27 Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024
Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH May 13
Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1 May 05
Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021) Apr 11
Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021) Feb 23
Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension Feb 15 Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023
Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023 Jan 27 Cereno Scientific Announces Changes in the Executive Management Team Dec 16
Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1 Dec 02 Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee
Third quarter 2022 earnings released: kr0.069 loss per share (vs kr0.047 loss in 3Q 2021) Nov 18
No independent directors Nov 16
Cereno Scientific's Patent Protection for Drug Candidate CS1 Expands in Mexico Through Its Second Patent Family Sep 08
Second quarter 2022 earnings released Aug 27 Cereno Scientific Reports First Patient Dosed in Phase II Study in PAH with Drug Candidate CS1
Cereno Scientific's Innovative Phase II Study Design in PAH with CS1 is Accepted for Presentation at the CHEST Annual Meeting on Oct. 16-19 in Nashville, US Aug 11
Cereno Scientific Announces Enrolling the First Patient in Its Phase II Clinical Study with Lead Drug Candidate Cs1 in Pulmonary Arterial Hypertension Jul 11
Cereno Scientific Reports First Patient Enrolled in Phase II Study in PAH with Drug Candidate CS1 Jul 07
Frejs Revisorer AB Announces Board Appointments Jun 02
Cereno Scientific AB Appoints Nick Oakes as Head of Preclinical Development May 31
Cereno Scientific AB (publ) to Report Q2, 2022 Results on Aug 25, 2022 May 20
First quarter 2022 earnings released May 20
Cereno Scientific's Abstract on CS1's Innovative Phase II Study Design Accepted At Top Pulmonary Vascular Congress PVRI Held in June, 2022 May 12 Cereno Scientific to Present Candidate Drug CS585 Preclinical Data At EHA 2022 - the Premier Medical Congress for Hematology May 10
Cereno Scientific Nominates Drug Candidate CS585 in PCA Program for Continued Development in Cardiovascular Disease Apr 28
No independent directors Apr 27
Full year 2021 earnings released: kr0.15 loss per share (vs kr0.22 loss in FY 2020) Apr 08
Cereno Scientific Appoints Fredrik Frick as Head of Clinical Operations Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 10 Cereno Scientific AB (publ) to Report Fiscal Year 2021 Final Results on Apr 06, 2022
Cereno Scientific Obtains Additional Patent Protection for Phase II Drug Candidate CS1 in Japan Jan 22 Shareholder Returns 4A1 DE Biotechs DE Market 7D 4.1% -2.1% 3.0% 1Y 2.9% -3.8% 12.8%
See full shareholder returns
Return vs Market: 4A1 underperformed the German Market which returned 13.4% over the past year.
Price Volatility Is 4A1's price volatile compared to industry and market? 4A1 volatility 4A1 Average Weekly Movement 8.0% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 4A1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4A1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases.
Show more Cereno Scientific AB (publ) Fundamentals Summary How do Cereno Scientific's earnings and revenue compare to its market cap? 4A1 fundamental statistics Market cap €127.35m Earnings (TTM ) -€7.05m Revenue (TTM ) €7.54m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4A1 income statement (TTM ) Revenue SEK 86.75m Cost of Revenue SEK 0 Gross Profit SEK 86.75m Other Expenses SEK 167.87m Earnings -SEK 81.12m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) -0.29 Gross Margin 100.00% Net Profit Margin -93.51% Debt/Equity Ratio 39.2%
How did 4A1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/19 02:55 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cereno Scientific AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jyoti Prakash Edison Investment Research Soo Romanoff Edison Investment Research
Show 0 more analysts 